SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 6, 2024 – July 24, 2024Lead Plaintiff Deadline: Dec. 13, 2024 Visit: www.hbsslaw.com/investor-fraud/ew Contact the Firm Now: EW@hbsslaw.com 844-916-0895 Class Action Lawsuit Against Edwards Lifesciences Corporation (EW): The litigation is focused on the propriety of Edwards Lifesciences’ disclosures about its ...

Have you evaluated the performance of Edwards Lifesciences' (EW) international operations during the quarter that concluded in September 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and gr ...

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards ...

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"), of the important December 13, 2024 lead plaintiff deadline. SO WHAT: If you purchased Edwards securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...

I discussed my "Strong Buy" thesis on Edwards Lifesciences Corporation (NYSE: EW ) in July 2024 and bought the dip after the company cut its guidance in Q2 FY24 . Since then, the stock price has surged by Analyst's Disclosure: I/we have a beneficial long position in the shares of EW either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationshi ...

LOS ANGELES, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"). If you suffered a loss on your Edwards Lifesciences investments or would like ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Oct. 25, 2024 /PRNewswire ...

Edwards Lifesciences Corporation (EW) reported third-quarter 2024 adjusted earnings per share (EPS) of 67 cents, in line with the Zacks Consensus Estimate. The figure increased 21.8% from the year-ago quarter's level. On this note, GAAP EPS from continuing operations was 61 cents compared with 55 cents in the third quarter of 2023. The quarter's one-time adjustments primarily include certain litigation expenses and amortization of intangible assets. In the quarter, the company completed the sale of Critical ...

Edwards Lifesciences (EW) reported $1.35 billion in revenue for the quarter ended September 2024, representing a year-over-year decline of 8.5%. EPS of $0.67 for the same period compares to $0.59 a year ago. ...

RADNOR, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...